HC Wainwright Has Positive Forecast for CANF Q3 Earnings

Can-Fite BioPharma Ltd. (NYSE:CANF) – Equities researchers at HC Wainwright lifted their Q3 2024 EPS estimates for Can-Fite BioPharma in a report released on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings of ($0.27) per share for the quarter, up from their prior estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at ($0.05) EPS.

A number of other research firms also recently issued reports on CANF. StockNews.com upgraded shares of Can-Fite BioPharma from a “sell” rating to a “hold” rating in a research note on Tuesday. EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

Can-Fite BioPharma Stock Performance

Shares of NYSE CANF opened at $2.07 on Thursday. The stock has a 50 day moving average price of $2.26 and a 200 day moving average price of $2.52. The firm has a market capitalization of $7.33 million, a price-to-earnings ratio of -1.16 and a beta of 1.39. Can-Fite BioPharma has a 52-week low of $1.83 and a 52-week high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC raised its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.